TABLE 4.
Point dose estimates required to achieve different pharmacodynamic endpoints against MRSA 33591 at different pretreatment titers in the mouse neutropenic thigh model
| Pretreatment titer and drug | Dose (mg/kg) for achieving pharmacodynamic endpointa
|
||||
|---|---|---|---|---|---|
| ED50 | EDstasis | ED1-log kill | ED2-log kill | ED3-log kill | |
| 4.9 log10 CFU/g (control) | |||||
| Telavancin | 1.2 | 1.8 | 4.7 | — | — |
| Vancomycin | 10.1 | 28.8 | 100 | — | — |
| 7.1 log10 CFU/g (high) | |||||
| Telavancin | 7.1 | 3.5 | 9.1 | 22.4 | 80 |
| Vancomycin | 61.2 | 42.6 | 87.1 | 288.4 | — |
a
Doses administered i.v. —, endpoint not achieved at the doses tested.